sulfasalazine has been researched along with Deficiency, IgG in 2 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Excerpt | Relevance | Reference |
---|---|---|
"Three per cent developed selective IgA deficiency between 8 and 20 weeks after starting SASP." | 1.28 | Immunodeficiencies associated with sulphasalazine therapy in inflammatory arthritis. ( Bacon, PA; Farr, M; Kitas, GD; Tunn, EJ, 1991) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (50.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Farr, M | 1 |
Kitas, GD | 1 |
Tunn, EJ | 1 |
Bacon, PA | 1 |
Leickly, FE | 1 |
Buckley, RH | 1 |
2 other studies available for sulfasalazine and Deficiency, IgG
Article | Year |
---|---|
Immunodeficiencies associated with sulphasalazine therapy in inflammatory arthritis.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Dysgammaglobulinemia; Female; Humans; IgA Deficiency | 1991 |
Development of IgA and IgG2 subclass deficiency after sulfasalazine therapy.
Topics: Child; Colitis, Ulcerative; Humans; IgA Deficiency; IgG Deficiency; Immunoglobulin M; Male; Sulfasal | 1986 |